Company Spotlight: Cercare Medical Virtual Expert - Mapping Brain Tumors and Blood Flow

In this episode, we unpack the FDA 510(k) summary for Cercare Medical's CMN Capillary Function with Oncology Virtual Expert. We explore how this software combines structural tumor volumes with capillary blood flow data, the reality of its 0.706 and 0.822 Dice similarity scores, and the strict scanning rules required for longitudinal tracking.

Key points

• The FDA cleared Cercare Medical's Oncology Virtual Expert as a Class II decision-support tool for adult patients with pathologically proven brain gliomas, WHO Grade II through IV.
• Unlike its cloud-based predicate device, the software runs locally on standard off-the-shelf computers or virtual platforms like VMware.
• Testing on a 100-patient dataset showed a mean Dice similarity coefficient of 0.706 for T1 enhancing regions and 0.822 for T2/FLAIR hyperintensity regions.
• The system automatically extracts perfusion data, such as tissue blood volume and flow, directly from the delineated tumor sub-components.
• Device labeling strictly instructs that longitudinal volumetric comparisons must be performed using the same scanner model and consistent acquisition parameters to minimize variability.

Source: FDA 510(k) summary K260316: CMN Capillary Function with Oncology Virtual Expert (Cercare Medical) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Cercare Medical (cercare-medical.com) · Product: CMN Capillary Function with Oncology Virtual Expert · FDA 510(k) K260316

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-cercare-medical-virtual-expert-mapping-brain-tumors-a3beb9